Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...
Pharmaceutical Technology on MSN
EC approves Incyte’s Minjuvi combo for follicular lymphoma
The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for ...
ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
The illustration depicts how during differentiation cells normally lose their plasticity and ability to acquire new fates.
News Medical on MSN
Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback